


Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression

Etienne Cavalier^{1*}, Julien Guiot^{2*}, Katharina Lechner^{3,4}, Alexander Dutsch^{3,4}, Mark Eccleston⁵, Marielle Herzog⁵, Thomas Bygott⁵, Adrian Schomburg^{6,7,8}, Theresa Kelly^{9*}, Stefan Holdenrieder^{10*}

Supplementary Figure 1



Supplementary Figure 1: Detection of circulating nucleosomes associated with H3.1 or H3R8Cit in plasma of COVID-19 patients with SARS or COVID-19 patients without SARS. Plasma from COVID-19 patients with SARS (n=25) and COVID-19 patients without SARS (n=10) were assayed with Nu.Q H3.1 (A) or Nu.Q H3R8Cit (B). COVID-19 patients were compared using a Wilcoxon-Mann-Whitney test and not significantly different from each other.